Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GOAL.MD vs Teleios Health

GOAL.MD
Graded #151

Higher grade

vs+8.200000000000003
Teleios Health
Graded #328

Lower grade

The verdict

GOAL.MD takes it — 68.4/100 to 60.2/100.

GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleios Health +20
64
84
Dose & formulationGOAL.MD +22
86
64
Clinical oversightGOAL.MD +19
68
49
Labs & monitoringGOAL.MD +5
53
48
FulfillmentGOAL.MD +35
77
42
Contract termsEven
55
55
GOAL.MD · left barTeleios Health · right bar

The numbers

MetricGOAL.MDTeleios Health
WeighScore68.4/10060.2/100
GradeCC
Scorecard rank#151#328
Semaglutide$179/mo$99/mo (starting dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)$139/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
GOAL.MD

Graded #151 · C

Strengths

  • Transparent dose-tiered pricing on brand pens
  • LegitScript Certified
  • Manual-renewal model — no surprise auto-billing
  • Free nutrition coach included
  • BBB A+ rating since 2021

Where it loses points

  • No named compounding pharmacy partner
  • Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
  • No URAC or PCAB pharmacy accreditation
Teleios Health

Graded #328 · C

Strengths

  • Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
  • Compounded tirzepatide from a competitive $139/mo floor
  • Markets physician (MD/DO) prescribing rather than an NP-only model
  • Clean meta-tag and SEO implementation

Where it loses points

  • Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
  • No named medical director, physician, or corporate entity disclosed
  • Year founded unknown — a newer floor-price entrant warranting extra scrutiny
  • No LegitScript, NABP, or SOC 2 trust signal found
  • Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard